

# Electron Kebebew

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/121672/publications.pdf>

Version: 2024-02-01

194  
papers

12,075  
citations

30070

54  
h-index

29157

104  
g-index

195  
all docs

195  
docs citations

195  
times ranked

12810  
citing authors

#	ARTICLE	IF	CITATIONS
1	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 1104-1139.	4.5	717
2	Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans. <i>Cell Metabolism</i> , 2014, 19, 302-309.	16.2	643
3	Anaplastic thyroid carcinoma. <i>Cancer</i> , 2005, 103, 1330-1335.	4.1	556
4	Medullary thyroid carcinoma. <i>Cancer</i> , 2000, 88, 1139-1148.	4.1	555
5	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
6	Adrenocortical carcinoma in the United States. <i>Cancer</i> , 2008, 113, 3130-3136.	4.1	426
7	The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer. <i>Annals of Surgery</i> , 2007, 246, 466-471.	4.2	407
8	Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?. <i>World Journal of Surgery</i> , 2006, 30, 872-878.	1.6	372
9	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 337-386.	4.5	297
10	The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. <i>Annals of Surgery</i> , 2020, 271, e21-e93.	4.2	290
11	Superiority of [ <sup>68</sup> Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of <sup>111</sup> In-SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2015, 21, 3888-3895.	7.0	223
12	Results of Laparoscopic Adrenalectomy for Suspected and Unsuspected Malignant Adrenal Neoplasms. <i>Archives of Surgery</i> , 2002, 137, 948.	2.2	212
13	American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making. <i>Thyroid</i> , 2015, 25, 760-768.	4.5	204
14	Integrated Genomic Analysis of <sup>1</sup> H <sup>1</sup> le Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018, 34, 256-270.e5.	16.8	195
15	Coexisting Chronic Lymphocytic Thyroiditis and Papillary Thyroid Cancer Revisited. <i>World Journal of Surgery</i> , 2001, 25, 632-637.	1.6	193
16	Differentiated Thyroid Cancer: "Complete" Rational Approach. <i>World Journal of Surgery</i> , 2000, 24, 942-951.	1.6	166
17	Predictors of Single-Gland vs Multigland Parathyroid Disease in Primary Hyperparathyroidism. <i>Archives of Surgery</i> , 2006, 141, 777.	2.2	155
18	<sup>68</sup> Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. <i>Journal of Nuclear Medicine</i> , 2016, 57, 186-191.	5.0	148

#	ARTICLE	IF	CITATIONS
19	Germline <i>HABP2</i> Mutation Causing Familial Nonmedullary Thyroid Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 448-455.	27.0	128
20	Prevalence, Clinicopathologic Features, and Somatic Genetic Mutation Profile in Familial Versus Sporadic Nonmedullary Thyroid Cancer. <i>Thyroid</i> , 2011, 21, 367-371.	4.5	127
21	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1949-1956.	5.0	119
22	GCM2 -Activating Mutations in Familial Isolated Hyperparathyroidism. <i>American Journal of Human Genetics</i> , 2016, 99, 1034-1044.	6.2	119
23	<sup>68</sup> Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3575-3581.	3.6	111
24	Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. <i>Endocrine Practice</i> , 2016, 22, 302-314.	2.1	110
25	Epigenetic Regulation of the lncRNA MEG3 and Its Target c-MET in Pancreatic Neuroendocrine Tumors. <i>Molecular Endocrinology</i> , 2015, 29, 224-237.	3.7	107
26	Parathyroid carcinoma. <i>Current Treatment Options in Oncology</i> , 2001, 2, 347-354.	3.0	106
27	Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2018, 24, 4030-4043.	7.0	106
28	A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. <i>Surgery</i> , 2006, 140, 960-967.	1.9	104
29	Clinical Features and Genetic Predisposition to Hereditary Nonmedullary Thyroid Cancer. <i>Thyroid</i> , 2009, 19, 1343-1349.	4.5	104
30	DNA Methylation Profiling Identifies Global Methylation Differences and Markers of Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1004-E1013.	3.6	98
31	Laparoscopic Adrenalectomy: The Optimal Surgical Approach. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2001, 11, 409-413.	1.0	92
32	miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. <i>Endocrine-Related Cancer</i> , 2014, 21, 517-531.	3.1	91
33	Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. <i>Surgery</i> , 2016, 159, 311-319.	1.9	91
34	Tertiary Hyperparathyroidism. <i>Archives of Surgery</i> , 2004, 139, 974.	2.2	83
35	Localization of Insulinoma Using <sup>68</sup> Ga-DOTATATE PET/CT Scan. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 195-199.	3.6	83
36	Management of anaplastic thyroid cancer. <i>Gland Surgery</i> , 2015, 4, 44-51.	1.1	82

#	ARTICLE	IF	CITATIONS
37	Extent of Disease and Practice Patterns for Medullary Thyroid Cancer. <i>Journal of the American College of Surgeons</i> , 2005, 200, 890-896.	0.5	77
38	Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer. <i>Thyroid</i> , 2009, 19, 953-956.	4.5	77
39	Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3458-3466.	7.0	73
40	Total Thyroidectomy or Thyroid Lobectomy in Patients with Low-risk Differentiated Thyroid Cancer: Surgical Decision Analysis of a Controversy Using a Mathematical Model. <i>World Journal of Surgery</i> , 2000, 24, 1295-1302.	1.6	72
41	Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. <i>Journal of the American College of Surgeons</i> , 2015, 221, 509-517.	0.5	72
42	Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 537-549.	27.6	72
43	Parathyroidectomy for primary hyperparathyroidism in octogenarians and nonagenarians. <i>Archives of Surgery</i> , 2003, 138, 867.	2.2	69
44	Hyperparathyroidism-jaw tumor syndrome: Results of operative management. <i>Surgery</i> , 2014, 156, 1315-1325.	1.9	68
45	miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression. <i>Cancer Research</i> , 2015, 75, 367-377.	0.9	67
46	Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 787-797.	6.4	64
47	Curbing Unnecessary and Wasted Diagnostic Imaging. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 245.	7.4	64
48	Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. <i>Endocrine-Related Cancer</i> , 2016, 23, 899-908.	3.1	62
49	Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. <i>Gastroenterology</i> , 2018, 154, 998-1008.e1.	1.3	62
50	Medullary thyroid cancer. <i>Current Treatment Options in Oncology</i> , 2000, 1, 359-367.	3.0	61
51	Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4498-4504.	3.6	60
52	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. <i>Surgery</i> , 2017, 161, 230-239.	1.9	60
53	Locally advanced differentiated thyroid cancer. <i>Surgical Oncology</i> , 2003, 12, 91-99.	1.6	59
54	Adrenal Incidentaloma. <i>New England Journal of Medicine</i> , 2021, 384, 1542-1551.	27.0	59

#	ARTICLE	IF	CITATIONS
55	Patient specific tumor growth prediction using multimodal images. <i>Medical Image Analysis</i> , 2014, 18, 555-566.	11.6	57
56	MiR-20a Is Upregulated in Anaplastic Thyroid Cancer and Targets LIMK1. <i>PLoS ONE</i> , 2014, 9, e96103.	2.5	57
57	Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. <i>Nature Communications</i> , 2018, 9, 4172.	12.8	56
58	Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 5044-5054.	7.0	54
59	Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. <i>Oncotarget</i> , 2015, 6, 9073-9085.	1.8	54
60	Hereditary Non-medullary Thyroid Cancer. <i>World Journal of Surgery</i> , 2008, 32, 678-682.	1.6	51
61	Should small papillary thyroid cancer be observed? A population-based study. <i>Cancer</i> , 2015, 121, 1017-1024.	4.1	51
62	Performance comparison of SNP detection tools with illumina exome sequencing data—an assessment using both family pedigree information and sample-matched SNP array data. <i>Nucleic Acids Research</i> , 2014, 42, e101-e101.	14.5	50
63	Lysyl Oxidase (LOX) Transcriptionally Regulates <i>SNAI2</i> Expression and TIMP4 Secretion in Human Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4491-4504.	7.0	50
64	miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer. <i>PLoS ONE</i> , 2015, 10, e0130496.	2.5	48
65	A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. <i>Clinical Endocrinology</i> , 2017, 86, 128-133.	2.4	48
66	MicroRNAs in the thyroid. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 603-619.	4.7	47
67	Results of Screening in Familial Non-Medullary Thyroid Cancer. <i>Thyroid</i> , 2017, 27, 1017-1024.	4.5	47
68	Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. <i>Surgery</i> , 2017, 161, 220-227.	1.9	47
69	Association of <i>VHL</i> Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. <i>JAMA Oncology</i> , 2018, 4, 124.	7.1	44
70	Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis. <i>Surgery</i> , 2016, 159, 1382-1389.	1.9	43
71	Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study. <i>World Journal of Surgery</i> , 2016, 40, 697-705.	1.6	43
72	Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3566-3573.	3.6	43

#	ARTICLE	IF	CITATIONS
73	GCMB gene, a master regulator of parathyroid gland development, expression, and regulation in hyperparathyroidism. <i>Surgery</i> , 2004, 136, 1261-1266.	1.9	39
74	Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure. <i>Annals of Surgical Oncology</i> , 2016, 23, 416-423.	1.5	39
75	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. <i>Frontiers in Oncology</i> , 2019, 9, 53.	2.8	39
76	An <i>In Vivo</i> Mouse Model of Metastatic Human Thyroid Cancer. <i>Thyroid</i> , 2014, 24, 695-704.	4.5	38
77	Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. <i>European Journal of Endocrinology</i> , 2017, 176, 575-582.	3.7	38
78	ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. <i>PLoS ONE</i> , 2014, 9, e101423.	2.5	36
79	Anaplastic thyroid cancer: Rare, fatal, and neglected. <i>Surgery</i> , 2012, 152, 1088-1089.	1.9	34
80	Quantitative High-Throughput Drug Screening Identifies Novel Classes of Drugs with Anticancer Activity in Thyroid Cancer Cells: Opportunities for Repurposing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E319-E328.	3.6	34
81	Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. <i>Surgery</i> , 2018, 163, 31-34.	1.9	34
82	Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors. <i>Cancer</i> , 2019, 125, 1247-1257.	4.1	34
83	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. <i>JAMA Surgery</i> , 2019, 154, 40.	4.3	34
84	Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis. <i>Annals of Surgical Oncology</i> , 2018, 25, 122-130.	1.5	33
85	Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. <i>Annals of Surgery</i> , 2020, 271, 399-410.	4.2	33
86	Assessment of Tumor Growth in Pancreatic Neuroendocrine Tumors in von Hippel Lindau Syndrome. <i>Journal of the American College of Surgeons</i> , 2014, 218, 163-169.	0.5	32
87	A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. <i>Surgery</i> , 2014, 156, 1378-1386.	1.9	32
88	Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. <i>Surgery</i> , 2018, 163, 191-196.	1.9	32
89	Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4123-4132.	7.0	31
90	Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. <i>BMJ Open</i> , 2015, 5, e008248-e008248.	1.9	29

#	ARTICLE	IF	CITATIONS
91	Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 319-329.	3.1	28
92	Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. <i>Nucleic Acids Research</i> , 2015, 43, 9327-9339.	14.5	28
93	Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity. <i>Carcinogenesis</i> , 2015, 36, 420-428.	2.8	28
94	Tumor growth prediction with reaction-diffusion and hyperelastic biomechanical model by physiological data fusion. <i>Medical Image Analysis</i> , 2015, 25, 72-85.	11.6	27
95	Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response. <i>Oncotarget</i> , 2018, 9, 33030-33042.	1.8	27
96	Prospective screening in familial nonmedullary thyroid cancer. <i>Surgery</i> , 2013, 154, 1194-1198.	1.9	26
97	Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma. <i>Cancer Medicine</i> , 2015, 4, 1060-1068.	2.8	26
98	The Rate and Clinical Significance of Incidental Thyroid Uptake as Detected by Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography. <i>Thyroid</i> , 2016, 26, 831-835.	4.5	26
99	Risk of Fracture Among Older Adults With Primary Hyperparathyroidism Receiving Parathyroidectomy vs Nonoperative Management. <i>JAMA Internal Medicine</i> , 2022, 182, 10.	5.1	26
100	Contemporary Management of Anaplastic Thyroid Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 78.	3.0	25
101	Feasibility of Radio-Guided Surgery with 68Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2015, 22, 676-682.	1.5	23
102	Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. <i>Oncotarget</i> , 2015, 6, 18038-18049.	1.8	23
103	Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism. <i>Annals of Surgical Oncology</i> , 2016, 23, 701-707.	1.5	22
104	Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. <i>Seminars in Oncology</i> , 2018, 45, 232-235.	2.2	22
105	Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer. <i>JAMA Network Open</i> , 2019, 2, e187754.	5.9	22
106	Phenylacetate Inhibits Growth and Vascular Endothelial Growth Factor Secretion in Human Thyroid Carcinoma Cells and Modulates Their Differentiated Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2840-2847.	3.6	21
107	Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3345-3352.	3.6	21
108	Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism. <i>Journal of the American College of Surgeons</i> , 2018, 226, 933-938.	0.5	21

#	ARTICLE	IF	CITATIONS
109	Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment. <i>Surgery</i> , 2019, 165, 50-57.	1.9	21
110	Surgery for adrenocortical carcinoma: When and how?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101408.	4.7	21
111	Undertreatment of primary hyperparathyroidism in a privately insured US population: Decreasing utilization of parathyroidectomy despite expanding surgical guidelines. <i>Surgery</i> , 2021, 169, 87-93.	1.9	21
112	NOP53 as A Candidate Modifier Locus for Familial Non-Medullary Thyroid Cancer. <i>Genes</i> , 2019, 10, 899.	2.4	20
113	The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors. <i>European Journal of Radiology</i> , 2019, 112, 130-135.	2.6	20
114	FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization. <i>World Journal of Surgery</i> , 2016, 40, 683-689.	1.6	19
115	National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5948-5956.	3.6	19
116	Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3285-3294.	3.6	19
117	Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1019-1029.	6.3	18
118	A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 187-195.	3.6	18
119	Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness. <i>Thyroid</i> , 2019, 29, 79-92.	4.5	18
120	Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer. <i>Oncotarget</i> , 2016, 7, 16517-16528.	1.8	18
121	Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms. <i>Clinical Cancer Research</i> , 2017, 23, 5302-5310.	7.0	17
122	Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2189-2198.	3.6	17
123	Patient Factors Associated With Parathyroidectomy in Older Adults With Primary Hyperparathyroidism. <i>JAMA Surgery</i> , 2021, 156, 334.	4.3	17
124	11â€œDeoxycortisol may be superior to cortisol in confirming a successful adrenal vein catheterization without cosyntropin: a pilot study. <i>International Journal of Endocrine Oncology</i> , 2017, 4, 75-83.	0.4	16
125	SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas. <i>Cell Reports</i> , 2022, 38, 110453.	6.4	16
126	Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. <i>Annals of Surgery</i> , 2019, 269, 741-747.	4.2	15



#	ARTICLE	IF	CITATIONS
127	A Combinatorial Strategy for Targeting <i>BRAF</i> V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib). <i>Clinical Cancer Research</i> , 2020, 26, 2022-2036.	7.0	15
128	Prospective Evaluation of the Clinical Utility of 18-Fluorodeoxyglucose PET CT Scanning in Patients with Von Hippel-Lindau-Associated Pancreatic Lesions. <i>Journal of the American College of Surgeons</i> , 2014, 218, 997-1003.	0.5	14
129	18F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. <i>Annals of Surgical Oncology</i> , 2016, 23, 714-721.	1.5	14
130	68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor. <i>International Journal of Endocrine Oncology</i> , 2018, 5, IJE04.	0.4	14
131	Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 567-577.	1.4	14
132	Long-Term Outcome of Bilateral Laparoscopic Adrenalectomy Measured by Disease-Specific Questionnaire in a Unique Group of Patients with Cushing's Syndrome. <i>Annals of Surgical Oncology</i> , 2015, 22, 699-706.	1.5	13
133	An update on familial nonmedullary thyroid cancer. <i>Endocrine</i> , 2020, 68, 502-507.	2.3	13
134	In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1631-1638.	3.6	12
135	MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. <i>Journal of Surgical Research</i> , 2019, 243, 1-7.	1.6	11
136	Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy. <i>Surgery</i> , 2020, 167, 224-232.	1.9	11
137	Adrenal Vein Sampling to Distinguish Between Unilateral and Bilateral Primary Hyperaldosteronism: To ACTH Stimulate or Not?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1447.	2.4	11
138	Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer. <i>PLoS ONE</i> , 2016, 11, e0149383.	2.5	11
139	Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules. <i>Clinical Endocrinology</i> , 2015, 83, 977-984.	2.4	10
140	Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3564-3567.	3.6	10
141	Lipofuscin Accumulation in Cortisol-Producing Adenomas With and Without PRKACA Mutations. <i>Hormone and Metabolic Research</i> , 2017, 49, 786-792.	1.5	10
142	Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype. <i>Cancer</i> , 2018, 124, 636-647.	4.1	10
143	Racial disparities in the utilization of parathyroidectomy among patients with primary hyperparathyroidism: Evidence from a nationwide analysis of Medicare claims. <i>Surgery</i> , 2022, 171, 8-16.	1.9	10
144	Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 714-720.	1.5	9

#	ARTICLE	IF	CITATIONS
145	Endocrine tumors associated with the vagus nerve. <i>Endocrine-Related Cancer</i> , 2016, 23, R371-R379.	3.1	9
146	Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III). <i>Frontiers in Oncology</i> , 2019, 9, 905.	2.8	9
147	Detection of insulinoma using (68)Gallium-DOTATATE PET/CT: a case report. <i>Gland Surgery</i> , 2014, 3, E1-5.	1.1	9
148	Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. <i>International Journal of Surgical Oncology</i> , 2017, 2017, 1-14.	0.6	8
149	Frequency and consequence of the recurrent YY1 p.T372R mutation in sporadic insulinomas. <i>Endocrine-Related Cancer</i> , 2018, 25, L31-L35.	3.1	8
150	Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. <i>Endocrine</i> , 2018, 61, 422-427.	2.3	8
151	Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. <i>Thyroid</i> , 2019, 29, 530-539.	4.5	8
152	Patients with differentiated thyroid cancer have a venous gradient in thyroglobulin levels. <i>Cancer</i> , 2007, 109, 1078-1081.	4.1	7
153	LOX is a novel mitotic spindle-associated protein essential for mitosis. <i>Oncotarget</i> , 2016, 7, 29023-29035.	1.8	7
154	Preoperative systemic inflammatory markers are prognostic indicators in recurrent adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2019, 120, 1450-1455.	1.7	7
155	Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors. <i>Radiology</i> , 2019, 290, 116-124.	7.3	7
156	Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2020, 27, 519-527.	3.1	7
157	GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3. <i>Oncotarget</i> , 2020, 11, 3354-3370.	1.8	7
158	Thyroid Cancer and Nonsteroidal Anti-Inflammatory Drug Use: A Pooled Analysis of Patients Older Than 40 Years of Age. <i>Thyroid</i> , 2015, 25, 1355-1362.	4.5	6
159	Comprehensive guidance on the diagnosis and management of primary mesenchymal tumours of the thyroid gland. <i>Lancet Oncology</i> , The, 2020, 21, e528-e537.	10.7	6
160	Genetic testing in endocrine surgery: Opportunities for precision surgery. <i>Surgery</i> , 2020, 168, 328-334.	1.9	6
161	Multimodal Image Driven Patient Specific Tumor Growth Modeling. <i>Lecture Notes in Computer Science</i> , 2013, 16, 283-290.	1.3	6
162	Somatic VHL Mutation in a Patient With MEN1-Associated Metastatic Pancreatic Neuroendocrine Tumor Responding to Sunitinib Treatment: A Case Report. <i>Journal of the Endocrine Society</i> , 2017, 1, 1124-1134.	0.2	5

#	ARTICLE	IF	CITATIONS
163	The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy. <i>Clinical Endocrinology</i> , 2018, 89, 481-488.	2.4	5
164	Factors associated with postoperative complications and costs for adrenalectomy in benign adrenal disorders. <i>Surgery</i> , 2022, 171, 1519-1525.	1.9	5
165	Kidney Stone Events Following Parathyroidectomy vs Nonoperative Management for Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2801-e2811.	3.6	5
166	Id1 Gene Expression and Regulation in Human Thyroid Tissue. <i>Thyroid</i> , 2005, 15, 522-530.	4.5	4
167	Insulinoma Due to Multiple Pancreatic Microadenoma Localized by Multimodal Imaging. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3559-3563.	3.6	4
168	High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy. <i>Surgery</i> , 2019, 165, 124-128.	1.9	4
169	Tumor growth modeling based on dual phase CT and FDG-PET. , 2013, , .		3
170	Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTc) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors—A Cohort Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 653401.	3.5	3
171	ATR-101 phase 1 clinical study for adrenocortical carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4585-TPS4585.	1.6	3
172	Repurposing existing drugs for the treatment of thyroid cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 369-371.	2.4	2
173	Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with life-threatening compressive symptoms. <i>Head and Neck</i> , 2015, 37, E205-8.	2.0	2
174	Thyroid Cancer: Is It All in the Genes?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 327-328.	6.3	2
175	Neural monitoring in endocrine neck surgery. <i>Gland Surgery</i> , 2018, 7, S86-S88.	1.1	2
176	Association of Parathyroidectomy With 5-Year Clinically Significant Kidney Stone Events in Patients With Primary Hyperparathyroidism. <i>Endocrine Practice</i> , 2021, 27, 948-955.	2.1	2
177	Reply to most patients with a small papillary thyroid carcinoma enjoy an excellent prognosis and may be managed with minimally invasive therapy or active surveillance. <i>Cancer</i> , 2015, 121, 3365-3366.	4.1	1
178	ASO Author Reflections: Systemic Inflammatory Markers in Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2018, 25, 874-875.	1.5	1
179	Aggressive resection of neuroendocrine tumor (NET) liver metastases: NET neutral or gain?. <i>Surgery</i> , 2019, 165, 176-177.	1.9	1
180	30th Anniversary and The Future of Thyroid. <i>Thyroid</i> , 2020, 30, 1-1.	4.5	1

#	ARTICLE	IF	CITATIONS
181	Probability of positive genetic testing in patients diagnosed with pheochromocytoma and paraganglioma: Criteria beyond a family history. <i>Surgery</i> , 2021, 169, 298-301.	1.9	1
182	Introduction to Papers Presented at the Orlo H. Clark Festschrift. <i>World Journal of Surgery</i> , 2009, 33, 368-368.	1.6	0
183	Nile Red Staining Helps Select Cells with Adrenocortical Progenitor Cell-Like Phenotype. <i>Journal of Surgical Research</i> , 2010, 161, 34-35.	1.6	0
184	Robotic Posterior Retroperitoneal Adrenalectomy: For What Benefit and at What Cost?. <i>Archives of Surgery</i> , 2012, 147, 275.	2.2	0
185	A Multidisciplinary journal focused on endocrine oncology. <i>International Journal of Endocrine Oncology</i> , 2014, 1, 1-1.	0.4	0
186	Quantitative reverse transcription polymerase chain reaction-based detection of thyroid-specific gene expression in fine-needle aspirate for thyroid cancer recurrence evaluation: A case report and review of the literature. <i>Head and Neck</i> , 2015, 37, E165-E168.	2.0	0
187	To the editor. <i>Npj Genomic Medicine</i> , 2017, 2, 21.	3.8	0
188	Ethnic specific differences in endocrine neoplasms: The role of susceptibility genes. <i>American Journal of Surgery</i> , 2018, 215, 1060-1061.	1.8	0
189	Solutions to Reduce Unnecessary Imaging—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2243.	7.4	0
190	Reply: Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment. <i>Surgery</i> , 2019, 165, 1246-1247.	1.9	0
191	Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer type-specific. <i>American Journal of Surgery</i> , 2019, 218, 14-17.	1.8	0
192	Editorial: Translational Research in Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020, 11, 224.	3.5	0
193	This Year in <i>Thyroid</i> and Farewell. <i>Thyroid</i> , 2021, 31, 1765-1765.	4.5	0
194	Treatment for Advanced and Metastatic Thyroid Cancer Refractory to Standard Treatment—We Need to Know the When, What, and Who. <i>JAMA Oncology</i> , 2022, 8, 250.	7.1	0